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Objectives: To estimate age at attaining Tanner stages in Ugandan/Zimbabwean HIV-
infected children initiating antiretroviral therapy (ART) in older childhood and inves-
tigate predictors of delayed puberty, particularly age at ART initiation.
Design: Observational analysis within a randomized trial.
Methods: Tanner staging was assessed every 24 weeks from 10 years of age, menarche
every 12 weeks and height every 4–6 weeks. Age at attaining different Tanner stages
was estimated using normal interval regression, considering predictors using multi-
variable regression. Growth was estimated using multilevel models with child-speciﬁc
intercepts and trajectories.
Results: Median age at ART initiation was 9.4 years (inter-quartile range 7.8, 11.3)
(n¼582). At the ﬁrst assessment, the majority (80.2%) were in Tanner stage 1; median
follow-up with staging was 2.8 years. There was a strong delaying effect of older age at
ART initiation on age at attaining all Tanner stages (P<0.05) and menarche (P¼0.02);
in boys the delaying effect generally weakened with older age. There were additional
signiﬁcant delays associated with greater impairments in pre-ART height-for-age Z-
score (P<0.05) in both sexes and pre-ART BMI-for-age in girls (P<0.05). There was no
evidence that pre-ART immuno-suppression independently delayed puberty or
menarche. However, older children/adolescents had signiﬁcant growth spurts in
intermediate Tanner stages, and were still signiﬁcantly increasing their height when
in Tanner stage 5 (P<0.01).
Conclusion: Delaying ART initiation until older childhood substantially delays pub-
ertal development and menarche, independently of immuno-suppression. This high-
lights that factors other than CD4
þ, such as pubertal development, need consideration
when making decisions about timing of ART initiation in older children.
Copyright  2015 Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
Globally, more than 3 million children/adolescents are
livingwithHIVinfection,andmorethan90%liveinsub-
Saharan Africa [1]. Of the 1.6 million HIV-infected
children/adolescents needing antiretroviral therapy
(ART) in 2012, only 34% were receiving it [2]. WHO
guidelines have increasingly promoted earlier ART,
recommending universal treatment for all children aged
below 2 years in 2010 [3] and below 5 years in 2013 [4].
However, historically substantial numbers of children in
sub-Saharan Africa have initiated ART at older ages.
Whilst studying long-term outcomes in those initiating
ART in infancy will be important over the coming
decades, survivors initiating ART in late childhood are
entering adolescence now, having experienced long
durations of untreated infection. They face considerable
challenges [5] that make long-term follow-up equally
important in this cohort.
One concern is puberty – both pubertal delay (and
associated impact including stigma) and the possibility of
major body shape changes. HIV has been associated with
delays in puberty, but relatively few studies have
considered the impact of age at ART initiation.
Furthermore, studies have predominantly been in
high-income settings [6–8], with one study in Uganda
[9].
Here, we use data from the AntiRetroviral Research fOr
Watoto (ARROW) trial, in which pubertal development
was assessed every 24 weeks in older children/adolescents
initiating ART in Uganda/Zimbabwe, to estimate the
impact of age at ART initiation in later childhood on
pubertal milestones, menarche, height and body shape
changes.
Methods
In the ARROW trial (ISRCTN24791884), previously
untreated Ugandan/Zimbabwean children/adolescents
aged 3 months to 17 years, eligible for ARTusing WHO
2006 criteria [10], were randomized 1:1 to clinically
driven monitoring vs. laboratory and clinical monitoring
for toxicityand efﬁcacy (CD4
þ) [11]. Noviral loads were
assayed in real time. Children were also randomized
1:1:1 in a factorial design to open-label lamivudi-
neþabacavirþnon-nucleoside reverse transcriptase
inhibitor (NNRTI) continuously (arm A, no zidovudine)
versus induction-maintenance with 4-drug regimen
lamivudineþabacavirþNNRTIþzidovudine for 36
weeks, followed by lamivudineþabacavirþNNRTI
(arm B; short-term zidovudine) or lamivudi-
neþabacavirþzidovudine (arm C; long-term zidovu-
dine). The NNRTI (nevirapine/efavirenz) was chosen by
clinicians according to local availability (varying by
country) and age. Caregivers gave written consent; older
children (8–17 years) aware of their HIV status also gave
assent/consent following national guidelines. Children
were recruited from three centres in Uganda and one in
Zimbabwe. The ARROW trial was approved by
Research Ethics Committees in Uganda, Zimbabwe
and the United Kingdom.
Weight and height were measured by nurses at enrolment
(ART initiation/baseline) and every 4–6 weeks sub-
sequently. At baseline and every 24 weeks, physicians
assessed Tanner staging [12] of pubic hair (P1–P5) and
genitalia (G1¼pre-pubertal to G5¼adult, males) or
breasts (B1–B5, females) in those aged at least 10 years.
Attainment of menarche (year and month) was assessed
in females every 12 weeks. In a separate metabolic sub-
study at the Joint Clinical Research Center and Harare
sites, consent was obtained to measure body circumfer-
ences (waist/hip/mid-thigh/mid-upper-arm) and skin-
fold thicknesses (triceps/sub-scapular/supra-iliac) every
24 weeks in those aged at least 10 years of age using
standardized procedures with pre-speciﬁed positions for
three repeated measurements [13]. Analysis used the mean
of these measurements. Height and BMI Z-scores were
calculated using WHO references [14,15] and anthro-
pometry Z-scores using Dutch references [16,17] (no
African data available).
Statistical analysis
Age at attaining Tanner stages 2, 3, 4 and 5 was
analysed for males (separately for genitalia and pubic
hair) and females (separately for breasts and pubic hair).
For individual children, the age when each transition
between stages occurred was known only to be between
the last observation of the previous stage and the ﬁrst
observation of the relevant stage (i.e. between assess-
ments). To account for this interval-censoring, normal
interval regression was used to estimate mean transition
age, assumed normally distributed (Supplementary
Methods, http://links.lww.com/QAD/A640) [18]. Age
at menarche was analysed similarly. Sensitivity analyses
used a time-to-event Weibull model allowing asymmetry
in the age distribution (results similar unless shown).
As G2 in boys and B2 in girls generally precedes P2 [19],
subsequentanalysesfocusedon timetoG2/B2(separately
in boys/girls), G3/B3, G4/B4, G5/B5 and menarche.
Factors considered as predictors were centre; ART-
strategy randomization; monitoring randomization;
age, CD4
þ, WHO stage, height/BMI-for-age at ART
initiation and change in CD4
þ and height/BMI-for-age
during the ﬁrst 6 months on ART (to reﬂect initial
response). Weight-for-age was not considered because
WHO standards onlyexist for those aged below 10 years,
and it was highly associated with height-for-age (Spear-
man correlation 0.73). As the ARROW trial recruited
over 18 months, birth cohort was co-linear with age at
ART initiation (Spearman correlation 0.98) and was
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therefore not considered. For G2/B2, backward
elimination (exit P¼0.05) was used to identify
important factors: all factors signiﬁcant in either model
were included in ﬁnal sex-speciﬁc models for G2/B2.
Models for G3/B3, G4/B4, G5/B5 and menarche
included the same factors, allowing trends in effects over
Tanner stages to be assessed. Non-linearity in effects of
continuous variables was explored using natural cubic
splines [20].
For the 539 (93.4%) children/adolescents in Tanner stage
1/2 at ﬁrst assessment, all height measurements aged
above 5 years (after which growth is approximately linear
[14]) were modelled separately for males and females
using multilevel models with a random intercept and
individual random slopes for each genitalia (male) or
breast (female) Tanner stage (unstructured correlation
matrix). Age was the underlying time-scale (Supple-
mentary Methods, http://links.lww.com/QAD/A640).
AnthropometricZ-scoresweremodelledusingmultilevel
modelswitharandominterceptandrandomslopesbefore
and after G2/B2 (unstructured correlation matrix), using
age as the underlying time-scale. Children already in G2/
B2 or higher at ﬁrst assessment were included using a
ﬁxed-effect indicator variable (missing transition age).
Randomized ART strategy was included as a ﬁxed effect
on intercept (Z-score at G2/B2 transition) and prior/
subsequent slopes to estimate associations with zidovu-
dineexposure given concerns aboutpotentiallipoatrophy
with thymidine analogues. A few (2.4%) outliers at least
1.25 Z-score different from both the previous and
following measurements were excluded (as was the ﬁrst/
last measurement if  1.25 Z-score different from the
following/previous measurement).
Analyses were performed using Stata 13.1 (StataCorp,
College Station, Texas, USA). P values were two-sided.
No adjustment was made a priori for multiple testing.
Results
Six hundred and twenty children reached their 10th
birthdayduringfollow-uporwereagedatleast 10yearsat
enrolment. Five hundred and eighty-two (93.9%) had at
least one assessment of Tanner staging or menarche; in
these children, Tanner staging and menarche were
assessed at 87.9 and 87.4% of scheduled visits after
10 years, respectively. Median age at ART initiation was
9.4 years [inter-quartile range (IQR) 7.8, 11.3; range
5.2–17.6) (Supplementary Table 1, http://links.lww.
com/QAD/A640). At ﬁrst Tanner assessment, most
(80.2%) were in stage 1 (median age 10.4 years), 13.2%
were in stage 2 (10.9 years) and 6.6% in stage 3/4/5
(13.9 years). Three hundred and forty-nine (60.5%)
children had already initiated ART at their ﬁrst Tanner
assessment. Median follow-up between ﬁrst and last
staging was 2.8 years (IQR 1.4, 3.7).
Tanner staging and menarche
In males, mean age at reaching G2 was 12.8 (3rd–97th
percentiles 10.0–15.5), P2 13.0 and adulthood (G5)
16.9years.Infemales,meanageatB2was11.7(3rd–97th
percentiles 9.4–14.0), P2 12.3, menarche 14.3 and
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Table 1. Age on reaching each Tanner stage and menarche.
Sex Stagea
Number of
children
contributing
measurement
Mean
age on
reaching
stage
(years) SE 95% CI
Percentiles
Mean/median
age Black
American US
children
[24,25]
Percentiles
in uninfected
Italian
controls [6]
3% 25% 75% 97% 3% 97%
Male G2 266 12.8 0.1 12.6, 13.0 10.0 11.8 13.8 15.5 9.3 9.4 13.3
G3 171 14.3 0.1 14.0, 14.6 10.9 13.1 15.5 17.6 11.8 11.0 14.0
G4 107 15.3 0.2 14.9, 15.7 11.7 14.0 16.7 19.0 13.4 12.3 14.8
G5 71 16.9 0.2 16.5, 17.3 14.3 16.0 17.8 19.5 14.9 – –
P2 270 13.0 0.1 12.8, 13.2 10.5 12.1 13.9 15.5 – 9.4 13.5
P3 161 14.3 0.1 14.1, 14.6 11.1 13.2 15.5 17.6 – 11.0 13.1
P4 109 15.3 0.2 14.9, 15.7 11.8 14.1 16.6 18.8 – 12.3 14.8
P5 69 16.8 0.2 16.4, 17.2 14.6 16.0 17.7 19.1 – – –
Female B2 273 11.7 0.1 11.6, 11.9 9.4 10.9 12.5 14.0 9.5 8.5 12.6
B3 236 13.1 0.1 12.9, 13.3 10.4 12.1 14.0 15.7 – 9.8 13.2
B4 179 14.4 0.1 14.1, 14.7 11.4 13.3 15.5 17.4 – 11.2 14.4
B5 107 16.1 0.2 15.7, 16.5 13.2 15.1 17.2 19.0 – – –
P2 284 12.3 0.1 12.1, 12.4 9.9 11.4 13.1 14.6 – 8.3 12.7
P3 219 13.5 0.1 13.3, 13.7 10.8 12.5 14.5 16.2 – 9.1 13.3
P4 161 14.5 0.1 14.3, 14.8 11.7 13.5 15.5 17.3 – 11.2 14.4
P5 107 16.5 0.2 16.1, 16.8 13.8 15.5 17.4 19.2 – – –
Menarche 303 14.3 0.1 14.1, 14.5 11.6 13.3 15.3 17.0 12.1 – –
Note: Time-to-event Weibull approach (see Methods section) resulted in similar estimates (e.g. G2 mean 12.6 years; B2 11.3; menarche 14.4). No
uninfected African control data available. The symbol ‘–’ indicates ‘not available’.
aTanner staging of genitalia (G1¼pre-pubertal to G5¼adult) in males or breasts (B1 to B5) in females, and pubic hair (P1 to P5) in both. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
adulthood (P5) 16.5 years (Table 1). At 12 years, 36% of
girls had not attained B2 (Fig. 1), 56% had not attained P2
and 58% had not attained both B2 and P2; at 13 years,
37%ofboyshadnotattainedG2,50%hadnotattainedP2
and 53% had not attained both G2 and P2.
Factors independently affecting age at attaining G2 or B2
were age at ART initiation; height and BMI Z-scores at
ART initiation; change in CD4
þ, height and BMI Z-
scores during the ﬁrst 6 months on ART and centre. To
allow comparison across stages, all these factors were
included in sex-speciﬁc models for G2/B2, G3/B3, G4/
B4, G5/B5 and menarche. There was a strong delaying
effect of initiating ARTat older rather than younger ages
on age at attaining each Tanner stage for boys and girls
(P<0.05) and for menarche (P¼0.02). Figure 2 shows
the relationship between age at ART initiation and
reaching different Tanner stages: being 1 year older at
ART initiation had different impacts on pubertal delay
depending on the speciﬁc age at ART initiation (i.e. non-
linear effects). For example, a boy initiating ARTaged 9
years would reach G2/G3/G4/G5 aged 13.3/14.0/14.4/
16.8 compared to 13.2/14.8/15.6/16.3 if initiating aged
11.SimilarlyagirlinitiatingARTaged9wouldreachB2/
B3/B4/B5 aged 11.8/12.7/13.7/14.6 compared to 12.3/
13.6/14.5/15.7 if aged 11. In boys, the delaying effect of
being older at ART initiation generally weakened with
increasing age: a boy initiating ARTaged 7 would reach
G2 0.5 years later than one who is aged 6; a boy aged 12
would reach G2 0.2 years later than one aged 11
(Supplementary Table 2, http://links.lww.com/QAD/
A640). In contrast, in girls, the delaying effect on age at
B2 in particular was stronger in those initiating at older
ages:agirlinitiatingARTaged7wouldreachB20.1years
later than one aged 6; a girl aged 12 would reach B2 0.5
years later than one aged 11. Sensitivity analyses with
Weibull-distributed transition ages gave broadly similar
results (Supplementary Figure 1, http://links.lww.com/
QAD/A640).
Independently of the strong association between age at
ART initiation and age at G2–G5 and B2–B5, pubertal
stages were consistently delayed even further in children
with lower pre-ART height-for-age (Fig. 3; Supple-
mentary Table 3, http://links.lww.com/QAD/A640).
For example, having one Z-score lower height-for-age at
ART initiation delayed G2 in boys by 0.4 years and B2 in
girls by 0.3 years. There was weak evidence of further
delays with relatively small increases in height-for-age
during the ﬁrst 6 months on ART. In girls, but not boys,
there were also independent consistent delays with lower
pre-ART BMI-for-age and relatively small initial
increases in BMI-for-age on ART. In boys, earlier G2
was independentlyassociated with greater initial increases
in CD4
þ on ART, but for G3–G5 and in girls there were
no statistically signiﬁcant effects. Transition ages also
varied on the basis of centre, with G2–G5 and B2–B4
reached earlier in boys and girls in the only non-urban
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Fig. 1. Distribution of Tanner staging by age and sex. Including closest to mid-point measurement per child in each age range. ( )
1¼pre-pubertal to 5¼adult. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
centre (Entebbe, Uganda) (Supplementary Table 3,
http://links.lww.com/QAD/A640). Centre effects were
strongest in males and at G2/B2. Other differences
between centres were smaller and inconsistent across
stages. There were no statistically signiﬁcant effects of
centre on age at menarche, and the impacts of the other
predictors described above were generally stronger for
menarche than for Tanner staging, suggesting less
measurement error in menarche. Fitting the ﬁnal sex/
stage-speciﬁc models separately in each centre resulted in
broadly consistent effects.
Pre-ART CD4
þ was not an independent predictor of G2
(P¼0.97 adjusting for factors above including CD4
þ
change during ﬁrst 6 months on ART) or B2 (P¼0.15),
and had no signiﬁcant independent effect on G3, B3, B5
and menarche (P>0.1; inverse associations with G4/B4
suggested over-ﬁtting; Supplementary Table 4, http://
links.lww.com/QAD/A640).
Previous studies have found household structure can
inﬂuence pubertal development. Considering additional
effects of the number of boys, girls, men ( 15 years) and
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Fig. 2. Impact of age at antiretroviral therapy initiation on age on reaching each Tanner stage and menarche (interval
regression). ( ) Absolute age at reaching different Tanner stages is presented at the reference category (mode or approximate
median) for other signiﬁcant predictors (see Supplementary Table 3 for full models, http://links.lww.com/QAD/A640), speciﬁcally
foraZimbabweanchildwithheightandBMI-for-age 2and 1atARTinitiation,and 2and 0.7sixmonthsafterARTinitiation;
and 250cells/ml increase in CD4
þ during the ﬁrst 6 months on ART. The effect of age at ART initiation (slope of line) does not
dependonthesefactors,buttheabsoluteagedoes.Tannerstagingofgenitalia(G1¼pre-pubertaltoG5¼adult)inmalesorbreasts
(B1 to B5) in females. Grey lines indicate overall mean/median age on reaching each Tanner stage and menarche in Black
American US children when available (no data for G3–G5 in girls). ART, antiretroviral therapy. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
women in the household at ART initiation, and adjusting
for factors above, we found that in girls, B5 was
signiﬁcantly earlier with more boys and/or men in the
household at ART initiation (both P¼0.03), and B4 was
marginally faster with more men in the household
(P¼0.07) (Supplementary Table 5, http://links.lww.-
com/QAD/A640). There was no evidence that more
boysor menaffectedageatB2,B3or menarche(P>0.1).
In boys, G2 was signiﬁcantly later with more boys in the
household (P¼0.05), with similar but weaker effects on
G3/G4 (0.05<P 0.1).
Growth
In boys, overall mean height growth varied across Tanner
stages: from 5 years of age to G2, it was 4.9cm/year [95%
conﬁdence interval (CI) 4.7, 5.1], accelerating slightly
during G2 (5.5cm/year, 95% CI 5.0, 6.0) and G3
(6.1cm/year, 95% CI 5.3, 6.9), before decreasing during
G4 (4.9cm/year, 95% CI 4.0, 5.8) and G5 (2.5cm/year,
95% CI 0.9, 4.0) (all P<0.01; heterogeneity P<0.001).
In girls, these effects were earlier and more pronounced
(G1–G5:5.4cm/year,95%CI5.2,5.7;7.1cm/year,95%
CI 6.7, 7.5; 5.3cm/year, 95% CI 4.8, 5.9; 2.8cm/year,
95% CI 2.3, 3.3 and 2.4cm/year, 95% CI 1.7, 3.2,
respectively; all P<0.001; heterogeneity P<0.001).
Children initiating ART at an older age grew slightly
more slowly than those initiating it at a younger age and,
as above, also experienced pubertal delay, which itself
impacts growth. Figure 4 displays the combined effect on
growth of initiating ART at three representative ages (8,
10or12years),incorporating itseffectsofTanner staging.
Forexample,aboyinitiatingARTat8yearswouldexpect
to be 143cm tall at G2 (13.3 years), compared to 139cm
(13.4 years) if ART was initiated at 12 years of age.
Interestingly, whilst girls normalized height on ART (e.g.
crossing WHO reference percentiles upwards), boys
remainedataconsiderableheightdisadvantage.However,
wewereunabletoreliablyestimatewhether thiswouldbe
detrimental to the ﬁnal height because follow-up during
G5/B5 was relatively short (median 0.5 years, IQR 0.2,
0.9).
Body circumferences and skin-fold thicknesses
In the metabolic sub-study, 326 children [156 (48%)
male] had anthropometric measurements available at
1110 visits aged at least 10 years (including 102 children
only observed in G2/B2, and 44 only in G2/B2 or
higher). Before G2/B2, anthropometric Z-scores were
decreasing very slightly (Supplementary Table 6, http://
links.lww.com/QAD/A640), signiﬁcantly so for waist/
hip/mid-thigh/mid-upper arm body circumferences and
supra-iliac skin-fold thickness. After G2/B2, all body
circumference Z-scores increased over time (by 0.1–0.2
Z-scores higher/year; P<0.0001 for all); skin-fold
thicknesses also increased, but changes were only
signiﬁcant for sub-scapular skin-folds (P¼0.03). There
were no signiﬁcant differences in changes in body
circumference or skin-fold thickness Z-scores before or
after G2/B2 between children receiving lamivudine/
abacavir/NNRTI throughout and either zidovudine for a
longer term, or just for 36 weeks (all P>0.1).
Discussion
Here we present longitudinal data from a large cohort
of older children in sub-Saharan Africa, followed for
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See Figure 2 for the effect of age at ART initiation. For point estimates and values within a 95% CI below the line at y¼0, one unit
higher value lowers the age at which the Tanner stage is attained. For point estimates and values within a 95% CI above the line at
y¼0, one unit higher value raises the age at which the Tanner stage is attained. ART, antiretroviral therapy. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
approximately 3 years on ART, having initiated treatment
mostlyaged approximately 7–12 years. Our main ﬁnding
is a substantial delay in pubertal stages and menarche
associated with initiating ART at older ages (Fig. 2),
unrelated to pre-ART immune-suppression. This high-
lights the importance of considering factors other than
current CD4
þ in decisions to initiate ART in older
children,suchasthepotentialfor pubertaldelayandlong-
termimmunereconstitution[21].Inparticular,itsuggests
that, regardless of immune parameters, vertically infected
children aged over 8 years may need to start ART to
reduce substantial pubertal delay. For example, recent
Ugandan guidelines recommend universal ART in all
vertically infected children aged below 15 years [22].
Our results contrast a recent US meta-analysis [8], which
found an effect of birth cohort rather than age at ART
initiation on pubertal delay. We were unable to assess
independenteffectsofbirthcohortandageasrecruitment
was over only 18 months; however, US children had a
wide range of birth years, whereas most ARROW
childrenincludedinthisanalysiswerebornbetween1996
and 2000 [8]. Importantly, the US study included many
children with mono/dual ARTexposure, so the effect of
age at initiation of combination ART in previously
untreated children could not be assessed; these children
also received combination ARTwith protease inhibitors
or NNRTIs. The fact that we deﬁnitively identiﬁed large
and consistent associations between later age at ART
initiation and pubertal delays in which birth cohort
covered a relatively narrow range and WHO-recom-
mended ﬁrst-line regimens were used, suggests that
previously identiﬁed birth cohort effects could be due to
complex confounding (by indication) between age at
initiation of combination ART, previous mono/dual
regimens and year of birth, as noted [8].
Independent of this association between age at ART
initiation and pubertal delay, we found additional
signiﬁcant delays associated with greater pre-ART
impairments in height Z-score and smaller initial height
responses on ART. These most likely reﬂect a child-
speciﬁc impact of untreated HIV on growth: the more
impaired a child’s growth has been by HIV for their age,
and the smaller any early ART-associated improvements,
thelonger thesubsequentpubertaldelay.Similareffectsof
pre-ART BMI and initial BMI response in girls, but not
boys,areplausiblyrelatedtodirectHIV-speciﬁceffectson
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Fig. 4. Dependence of growth on Tanner staging and age at antiretroviral therapy initiation in comparison to WHO growth
standards.EachsolidcolouredlineindicatestheestimatedheightatARTinitiation,andsubsequentgrowthforachildaged8,10or
12 years at ART initiation, in comparison with WHO standards (grey lines). Vertical lines indicate the expected age at each Tanner
transitions forthese ages atART initiation (estimated atreferencecategories for othersigniﬁcant predictors as per Figure2, i.e.fora
ZimbabweanchildwithheightandBMI-for-age 2 and 1atARTinitiation, and 2and 0.7sixmonthsafterARTinitiation;and
250cells/ml increase in CD4
þ during the ﬁrst 6 months on ART). Growth predictions assume linear growth in between these
transitions (as per multilevel models; see Methods section). ART, antiretroviral therapy. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
sexual maturation. HIV may impair growth and puberty
in several common ways, including nutritional
deﬁciencies, recurrent infections and chronic immune
activation, which may all skew endocrine axes. In other
childhood diseases characterized by chronic inﬂam-
mation, such as Crohn’s disease [23], the combination of
under-nutrition and elevated pro-inﬂammatory cyto-
kinescausesreductionsininsulin-likegrowth factor1and
alterations in gonadotrophin-releasing hormone-
secretion patterns, delaying growth and puberty. It is
likely thatgonadotrophinand growthhormoneresistance
similarly occur in HIV-infected children, with greater
delays in ART initiation exposing children to longer
periods of uncontrolled viral replication and chronic
inﬂammation, exacerbating impairments in linear growth
and puberty.
In contrast to the previous studies, we did not ﬁnd
consistenteffectsofmoremeninthehouseholdhastening
female development, other than for B5 (and marginally
for B4). This could reﬂect an overwhelming inﬂuence of
HIVon development. Alternatively, this could be because
African household structures may be more variable and
this was assessed at ART initiation, not longitudinally;
men/boys might be variably present due to absence for
work/boarding school, and/or because HIV-infected
children commonly move between carers/households.
We did ﬁnd a small but consistent effect of more boys in
the household delaying male development (G2–G4),
which could reﬂect restriction of access to assets
(including food).
Of note, we found no evidence for independent effects of
immune-suppression at ART initiation, although boys
with greater initial CD4
þ increases on ARTreached G2
slightlyearlier than those with poorer immune responses.
In contrast, a study of 983 HIV-infected US older
children/adolescents found consistent effects of immune-
suppression [7], which was conﬁrmed in the US meta-
analysis [8]. However, these studies included children
initiating combination ART with and without previous
mono/dual ARTexposure, so were unable to investigate
the impact of height/BMI-for-age at ART initiation in
those previously untreated. Pre-ART growth could be a
more sensitive marker of underlying developmental
problems than immuno-suppression, as it integrates
various insults, including infection (related and unrelated
to pre-ART CD4
þ, e.g. tuberculosis), growth hormone
resistance, micronutrient deﬁciency, inﬂammation, pov-
erty and food insecurity. In high-income countries,
immune-suppression may capture most of these effects.
Overall, our estimates of mean age at different Tanner
stages are broadly similar to HIV-infected girls in an
Italian study in 2001 [6], but boys showed a delay of
approximately 0.5 years compared to these children, and
both sexes were delayed by approximately 1 year
compared with the large US meta-analysis [8].
Correspondingly, much higher proportions had delayed
pubertal onset (56 vs. 4% in [8]). Both sexes were delayed
by approximately 1–2 years compared to uninfected
Italian controls [6], and boys by approximately 2–3 years
and girls by approximately 2 years compared to
uninfected Black American children [24,25]. Interest-
ingly, there appear to be few published data on the
variability of individual children around these means:
compared to the uninfected Italians, 3rd–97th percentiles
of ages at various Tanner stageswere approximately 1year
lower and 2 years higher. Before analysis, we hypoth-
esized that this lack of symmetry in the age distribution at
different pubertal stages [19] could be important. We
therefore also considered Weibull models, allowing more
individuals to be above or below the mean. Results were
broadly similar, suggesting the asymmetry is not
sufﬁciently severe to substantially affect models.
Clinically,adolescentswouldbeexpectedtostopgrowing
in Tanner stage 5, and WHO (and other) references
indicate little growth after 16 years in girls and 17 years in
boys [14]. ARROW children, however, were still
growing signiﬁcantly in G4/B4 and G5/B5, consistent
with delay in calciﬁcation of the growth plates. The
normal sequence of puberty in HIV-infected children is
not well characterized, and it is plausible that discordance
in pubertal stages occurs in chronic HIV infection. The
fact that growth continued in late adolescence may reﬂect
the ‘advantage’delayed puberty affords for linear growth,
meaning ﬁnal height may be rescued to some extent
because of the greater potential for catch-up growth than
that anticipated on the basis of age and/or pubertal stage
alone. There is emerging interest in the potentialwindow
of opportunity that adolescence provides [26] for catch-
up linear growth in low-income countries where early
childhood stunting is common, even outside HIV
infection. However, our results show the importance
of early ART, because the greater the growth impairment
at treatment initiation, the greater the requirement for
catch-up growth, which is eventually limited by growth
plate senescence.
There have been case reports of lipodystrophy developing
very quickly at puberty [27,28]. With long-term abacavir
andzidovudine-basedregimens,wefoundnoevidenceof
decreasing body circumferences/skin-fold thicknesses-
for-age associated with transition into puberty. Whilst
absolute Z-scores may be inﬂuenced by the reference
population, changes are more likely to be preserved. Our
results reassuringly suggest that signiﬁcant lipodystrophy
in adolescence is unusual with these currently recom-
mended antiretrovirals, at least in the medium term.
Our study has several limitations. A few children were
already in Tanner stage 2 at their ﬁrst assessment at
approximately 10 years: ideally Tanner staging should
have started earlier ( 9 years). Although effects of centre
on age at various pubertal stages highlight the potential
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for inter-observer variation to affect staging [29], centre-
speciﬁc models produced broadly similar estimates,
suggesting overall associations with different factors are
relatively robust. Furthermore, in girls, predictors of
Tanner staging were similar to menarche, which is much
less subject to observer (and recall) bias. Viral load – a
predictor of pubertal delay in the US meta-analysis [8] –
was only measured in 49% of the ARROW children at
ART initiation (those recruited post-June 2008), so could
not be considered; in the US study, associations with viral
load were independent of BMI and height-for-age
Z-scores.
In summary, untreated HIV infection in later childhood
leads to substantial delays in puberty and menarche,
independent of its effect on CD4
þ, with greater
impairments in height-for-age pre-ART magnifying
these effects. However, once on ART, these children
appear to beneﬁt from a prolonged window of
opportunity during which they continue to grow
throughout older adolescence. These results highlight
the importance of considering factors other than current
CD4
þ to guide ART initiation in older children. Future
studies should explore the impact of under-nutrition,
viral replication and chronic inﬂammation on endocrine
axes to better understand the factors inﬂuencing linear
growth and puberty in HIV-infected older children
and adolescents.
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